Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Melanoma 2Small Cell Lung Carcinoma 1Sarcoma 1Parathyroid Neoplasms 1Neoplasms 1Lung Neoplasms 1Kidney Neoplasms 1Colonic Neoplasms 1Carcinoid Tumor 1Breast Neoplasms 1

Interventions

pembrolizumab 15Nivolumab 9atezolizumab 5Ipilimumab 4Drug Therapy 4Docetaxel 4Radiotherapy 3Radiosurgery 3Paclitaxel 3Gemcitabine 3Cetuximab 3Carboplatin 3Blood Specimen Collection 3temsirolimus 2spartalizumab 2sargramostim 2motexafin gadolinium 2liposomal doxorubicin 2entinostat 2durvalumab 2belinostat 2Sirolimus 2Psychiatric Rehabilitation 2Peripheral Blood Stem Cell Transplantation 2Metformin 2Irinotecan 2Fluorouracil 2Etoposide 2Dexamethasone 2Cyclophosphamide 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Kidney Neoplasms × Dacarbazine × Thoracic × Clear all
NCT00600496 2026-05-27

A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)

AstraZeneca

Phase 1 Completed
140 enrolled
BreastDermatologicGastrointestinalGenitourinaryThoracic

Breast Neoplasms, Colonic Neoplasms, Kidney Neoplasms, Lung Neoplasms, Melanoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡